Advertisement

Immunologic Research

, Volume 65, Issue 1, pp 172–185 | Cite as

Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits

  • Manca Ogrič
  • Matic Terčelj
  • Sonja Praprotnik
  • Matija Tomšič
  • Borut Božič
  • Snezna Sodin-Semrl
  • Saša Čučnik
Therapeutic Aspects in Autoimmunity

Abstract

About a third of patients with rheumatoid arthritis treated with adalimumab may develop anti-adalimumab antibodies. Anti-adalimumab antibodies are associated with reduced drug levels, loss of drug efficacy, clinical non-response and an increased risk of adverse effects. In case of suspected drug failure and in order to better define clinical efficacy, adalimumab as well as anti-adalimumab antibodies levels should be monitored. Sandwich or indirect enzyme-linked immunoassay is most commonly used for determining adalimumab, while bridging ELISA and antigen-binding test are most useful for determining anti-adalimumab antibodies. Most current assays cannot detect antibodies complexed with the adalimumab; however, methods for dissociation of the complexes using acid/temperature have been developed. The aim of this review is to report on the latest methodology for detecting adalimumab and anti-ADL antibodies, benefits of their detections in clinical practice, as well as expose problematic issues, such as different analytical sensitivity and specificity, standardization and validation. The main problem in measuring adalimumab or anti-ADL antibodies is high drug sensitivity, which can result in false-negative anti-ADL antibodies. Therefore, drug-tolerant assays have been developed. Cell-based assays, such as the reporter gene assay, are recommended for detection of functionally active adalimumab and their neutralizing anti-ADL antibodies.

Keywords

Adalimumab Anti-drug antibodies Inflammatory autoimmune diseases Methodology TNF-α inhibitors Rheumatoid arthritis 

Notes

Acknowledgments

This study was supported by the Slovenian Research agency, National Research Programme P3-0314, 2015-2020 (to S.SS., Department of Rheumatology, University Medical Centre Ljubljana, Slovenia).

References

  1. 1.
    Schaeverbeke T, et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford). 2016;55(2):210–20.CrossRefGoogle Scholar
  2. 2.
    Marinari B, et al. Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations. Drug Dev Res. 2014;75(Suppl 1):S11–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Maxwell LJ et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015; 4: p. CD005468.Google Scholar
  4. 4.
    Zisapel M, et al. Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis. J Rheumatol. 2015;42(1):73–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947–55.CrossRefPubMedGoogle Scholar
  6. 6.
    Humira (Adalimumab). Web page. 24.11.2015. www.humira.com.
  7. 7.
    Remicade (Infliximab). Web page. 24 Aug 2015. www.remicade.com.
  8. 8.
    Enbrel (Etanercept). Web page. 24 Aug 2015. www.enbrel.com.
  9. 9.
    Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903–11.CrossRefPubMedGoogle Scholar
  10. 10.
    Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009;21(3):211–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Mazilu D, et al. Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment. Biomed Res Int. 2014;2014:702701.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Keiserman M, et al. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Rev Clin Immunol. 2014;10(8):1049–57.CrossRefPubMedGoogle Scholar
  13. 13.
    Jung YO, Kim HA. Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis. Korean J Intern Med. 2012;27(4):378–87.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Weinblatt ME, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45.CrossRefPubMedGoogle Scholar
  15. 15.
    Jespers LS, et al. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (NY). 1994;12(9):899–903.CrossRefGoogle Scholar
  16. 16.
    Radstake TR, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68(11):1739–45.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang SL, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal. 2013;78–79:39–44.CrossRefPubMedGoogle Scholar
  18. 18.
    Lallemand C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. J Immunol Methods. 2011;373(1–2):229–39.CrossRefPubMedGoogle Scholar
  19. 19.
    Eng GP, et al. Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study. Arthritis. 2015;2015:784825.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dekker LJ, et al. An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions. Anal Bioanal Chem. 2011;399(3):1081–91.CrossRefPubMedGoogle Scholar
  21. 21.
    van Schouwenburg PA, et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010;362(1–2):82–8.CrossRefPubMedGoogle Scholar
  22. 22.
    van Schouwenburg PA, et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis. 2013;72(10):1680–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Bloem K, et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods. 2015;418:29–38.CrossRefPubMedGoogle Scholar
  24. 24.
    Hart MH, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods. 2011;372(1–2):196–203.CrossRefPubMedGoogle Scholar
  25. 25.
    Pouw MF, et al. Key findings towards optimising adalimumab treatment: the concentration–effect curve. Ann Rheum Dis. 2015;74(3):513–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32(10):1429–35.CrossRefPubMedGoogle Scholar
  27. 27.
    Bartelds GM, et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther. 2010;12(6):R221.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bartelds GM, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921–6.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    van Schouwenburg PA, et al. IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol. 2012;32(5):1000–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Desvignes C, et al. Development and validation of an enzyme-linked immunosorbent assay to measure adalimumab concentration. Bioanalysis. 2015;7(10):1253–60.CrossRefPubMedGoogle Scholar
  31. 31.
    Hock BD, et al. Development of an ELISA based competitive binding assay for the analysis of drug concentration and anti-drug antibody levels in patients receiving adalimumab or infliximab. Ther Drug Monit. 2016;38:32–41.CrossRefPubMedGoogle Scholar
  32. 32.
    Ternant D, et al. Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015;79(2):286–97.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Bartelds GM, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Grampp G, Felix T. Pharmacovigilance considerations for biosimilars in the USA. BioDrugs. 2015;29(5):309–21.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Cai XY, et al. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development. Bioanalysis. 2012;4(17):2169–77.CrossRefPubMedGoogle Scholar
  36. 36.
    Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis. 2013;5(5):561–74.CrossRefPubMedGoogle Scholar
  37. 37.
    Meroni PL, et al. New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: a systematic analysis. Autoimmun Rev. 2015;14(9):812–29.CrossRefPubMedGoogle Scholar
  38. 38.
    Bendtzen K. Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy. 2012;4(11):1167–79.CrossRefPubMedGoogle Scholar
  39. 39.
    Bendtzen K. Immunogenicity of anti-TNF-alpha biotherapies: I. Individualized medicine based on immunopharmacological evidence. Front Immunol. 2015;6:152.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Bendtzen K, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44(7):774–81.CrossRefPubMedGoogle Scholar
  41. 41.
    Weisman MH, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700–21.CrossRefPubMedGoogle Scholar
  42. 42.
    Chen DY, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):e16.CrossRefPubMedGoogle Scholar
  43. 43.
    Llinares-Tello F, et al. Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis. Reumatología Clinica. 2014;10(2):105–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Llinares-Tello F, et al. Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int. 2014;34(12):1701–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Bandres Ciga S, et al. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies. J Clin Rheumatol. 2015;21(3):115–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Jani M, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol (Hoboken, NJ). 2015;67(8):2011–9.CrossRefGoogle Scholar
  47. 47.
    Valor L, et al. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison. Clin Exp Rheumatol. 2015;33(5):617–23.PubMedGoogle Scholar
  48. 48.
    Wolbink GJ, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(5):704–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Food and Drug Administration. Guidance for industry: bioanalytical method validation. 2001. http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf. Accessed 24 Nov 2015.
  50. 50.
    Tovey MG, Lallemand C. Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals. Bioanalysis. 2012;4(17):2179–90.CrossRefPubMedGoogle Scholar
  51. 51.
    McCutcheon KM, Quarmby V, Song A. Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interference. J Immunol Methods. 2010;358(1–2):35–45.CrossRefPubMedGoogle Scholar
  52. 52.
    Steenholdt C, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease. Ther Drug Monit. 2013;35(4):530–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Bender NK, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 2007;27(3):269–74.CrossRefPubMedGoogle Scholar
  54. 54.
    Bourdage JS, et al. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods. 2007;327(1–2):10–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Rispens T, et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods. 2012;375(1–2):93–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Llinares-Tello F, et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med. 2012;50(10):1845–7.CrossRefPubMedGoogle Scholar
  57. 57.
    van Schouwenburg PA, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72(1):104–9.CrossRefPubMedGoogle Scholar
  58. 58.
    van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164–72.CrossRefPubMedGoogle Scholar
  59. 59.
    Rispens T, et al. Drug interference in immunogenicity assays depends on valency. J Pharm Biomed Anal. 2013;85:179–85.CrossRefPubMedGoogle Scholar
  60. 60.
    Jung SM, et al. Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis. Int Immunopharmacol. 2014;21(1):20–5.CrossRefPubMedGoogle Scholar
  61. 61.
    Chen JS, et al. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis. Arthritis Care Res (Hoboken). 2014;66(3):464–72.CrossRefGoogle Scholar
  62. 62.
    van Schie KA, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015;74(1):311–4.CrossRefPubMedGoogle Scholar
  63. 63.
    Bendtzen K. Immunogenicity of anti-TNF-α biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front Immunol, 2015; 6.Google Scholar
  64. 64.
    Mire-Sluis AR, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1–2):1–16.CrossRefPubMedGoogle Scholar
  65. 65.
    Bendtzen K, et al. Monitoring immunogenicity of protein-based TNF antagonists. Frontline Gastroenterol. 2015.Google Scholar
  66. 66.
    Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol. 2008;20(4):431–5.CrossRefPubMedGoogle Scholar
  67. 67.
    Food and Drug Administration. Guidance for industry: assay development for immunogenicity testing of therapeutic proteins. 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf. Accessed 24 Nov 2015.
  68. 68.
    European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004007/WC500200380.pdf. Accessed 24 Nov 2015.  
  69. 69.
    Jolicoeur P, Tacey RL. Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach. Bioanalysis. 2012;4(24):2959–70.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Manca Ogrič
    • 1
  • Matic Terčelj
    • 1
  • Sonja Praprotnik
    • 1
  • Matija Tomšič
    • 1
    • 2
  • Borut Božič
    • 1
    • 3
  • Snezna Sodin-Semrl
    • 1
    • 4
  • Saša Čučnik
    • 1
    • 3
  1. 1.Department of RheumatologyUniversity Medical Centre-LjubljanaLjubljanaSlovenia
  2. 2.Faculty of MedicineUniversity of LjubljanaLjubljanaSlovenia
  3. 3.Chair of Clinical Biochemistry, Faculty of PharmacyUniversity of LjubljanaLjubljanaSlovenia
  4. 4.Natural Sciences and Information Technologies, Faculty of MathematicsUniversity of PrimorskaKoperSlovenia

Personalised recommendations